Skip to main content

Bender Jeremy's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed May 19, 2025

Accession no.
0001415889-25-013676
Filed
May 19, 2025
Trade date
May 15-16, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $87.4K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bender JeremyCIK 0001863107Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 15, 2025Common StockMOption exerciseAcquired+3,562––131,577Direct
May 15, 2025Common StockMOption exerciseAcquired+4,750––136,327Direct
May 15, 2025Common StockMOption exerciseAcquired+11,687––148,014Direct
May 15, 2025Common StockMOption exerciseAcquired+11,687––159,701Direct
May 16, 2025Common StockSSaleDisposed−13,964$6.26−$87,414.64145,737Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 15, 2025Common StockMOption exerciseDisposed−3,562$0.00$07,132Direct
May 15, 2025Common StockMOption exerciseDisposed−4,750$0.00$028,500Direct
May 15, 2025Common StockMOption exerciseDisposed−11,687$0.00$0116,878Direct
May 15, 2025Common StockMOption exerciseDisposed−11,687$0.00$0163,626Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)